Suboxone

RSS

Withdrawn

This medicine's authorisation has been withdrawn

buprenorphine / naloxone
MedicineHumanWithdrawn

Romanian is available via eTranslation, the European Commission's machine translation service.

Translate to Romanian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 11 September 2026, the European Commission withdrew the marketing authorisation for Suboxone (buprenorphine / naloxone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Indivior Europe Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Suboxone was granted marketing authorisation in the EU on 26 September 2006 for the substitution treatment of opioid drug dependence, within a framework of medical, social and psychological treatment. Suboxone was used in adults and adolescents over 15 years of age who had agreed to be treated for addiction.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011.

Several therapeutic alternatives remain available, as either buprenorphine alone or buprenorphine in combination with naloxone, in different pharmaceutical forms.

български (BG) (154.63 KB - PDF)

Vizualizare

español (ES) (126.92 KB - PDF)

Vizualizare

čeština (CS) (150.58 KB - PDF)

Vizualizare

dansk (DA) (127.12 KB - PDF)

Vizualizare

Deutsch (DE) (130.69 KB - PDF)

Vizualizare

eesti (ET) (123.34 KB - PDF)

Vizualizare

ελληνικά (EL) (155.89 KB - PDF)

Vizualizare

français (FR) (128 KB - PDF)

Vizualizare

hrvatski (HR) (150.39 KB - PDF)

Vizualizare

italiano (IT) (126.79 KB - PDF)

Vizualizare

latviešu (LV) (168.28 KB - PDF)

Vizualizare

lietuvių (LT) (152 KB - PDF)

Vizualizare

magyar (HU) (149.14 KB - PDF)

Vizualizare

Malti (MT) (152.23 KB - PDF)

Vizualizare

Nederlands (NL) (127.66 KB - PDF)

Vizualizare

polski (PL) (153.03 KB - PDF)

Vizualizare

português (PT) (129.04 KB - PDF)

Vizualizare

română (RO) (148.26 KB - PDF)

Vizualizare

slovenčina (SK) (152.34 KB - PDF)

Vizualizare

slovenščina (SL) (149.23 KB - PDF)

Vizualizare

suomi (FI) (125.71 KB - PDF)

Vizualizare

svenska (SV) (126.4 KB - PDF)

Vizualizare

Product information

български (BG) (1.02 MB - PDF)

Vizualizare

español (ES) (759.51 KB - PDF)

Vizualizare

čeština (CS) (1001.99 KB - PDF)

Vizualizare

dansk (DA) (886.16 KB - PDF)

Vizualizare

Deutsch (DE) (912.04 KB - PDF)

Vizualizare

eesti (ET) (973.17 KB - PDF)

Vizualizare

ελληνικά (EL) (1.07 MB - PDF)

Vizualizare

français (FR) (1016.58 KB - PDF)

Vizualizare

hrvatski (HR) (959.44 KB - PDF)

Vizualizare

italiano (IT) (898.18 KB - PDF)

Vizualizare

latviešu (LV) (968.27 KB - PDF)

Vizualizare

lietuvių (LT) (949.26 KB - PDF)

Vizualizare

magyar (HU) (1018.05 KB - PDF)

Vizualizare

Malti (MT) (1017.44 KB - PDF)

Vizualizare

Nederlands (NL) (876.74 KB - PDF)

Vizualizare

polski (PL) (1016.8 KB - PDF)

Vizualizare

português (PT) (890.47 KB - PDF)

Vizualizare

română (RO) (1.03 MB - PDF)

Vizualizare

slovenčina (SK) (1.02 MB - PDF)

Vizualizare

slovenščina (SL) (950.21 KB - PDF)

Vizualizare

suomi (FI) (887.75 KB - PDF)

Vizualizare

svenska (SV) (889.06 KB - PDF)

Vizualizare

Íslenska (IS) (870.77 KB - PDF)

Vizualizare

norsk (NO) (868.11 KB - PDF)

Vizualizare
Latest procedure affecting product information:PSUSA/00002113/202309
24/07/2024
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (87.43 KB - PDF)

Vizualizare

español (ES) (65 KB - PDF)

Vizualizare

čeština (CS) (104.93 KB - PDF)

Vizualizare

dansk (DA) (66.01 KB - PDF)

Vizualizare

Deutsch (DE) (66.19 KB - PDF)

Vizualizare

eesti (ET) (65.48 KB - PDF)

Vizualizare

ελληνικά (EL) (87.8 KB - PDF)

Vizualizare

français (FR) (68.57 KB - PDF)

Vizualizare

hrvatski (HR) (82.73 KB - PDF)

Vizualizare

italiano (IT) (63.93 KB - PDF)

Vizualizare

latviešu (LV) (85.72 KB - PDF)

Vizualizare

lietuvių (LT) (85.09 KB - PDF)

Vizualizare

magyar (HU) (74.75 KB - PDF)

Vizualizare

Malti (MT) (88.02 KB - PDF)

Vizualizare

Nederlands (NL) (64.63 KB - PDF)

Vizualizare

polski (PL) (89.14 KB - PDF)

Vizualizare

português (PT) (65.5 KB - PDF)

Vizualizare

română (RO) (75.31 KB - PDF)

Vizualizare

slovenčina (SK) (103.63 KB - PDF)

Vizualizare

slovenščina (SL) (103.72 KB - PDF)

Vizualizare

suomi (FI) (64.66 KB - PDF)

Vizualizare

svenska (SV) (86.31 KB - PDF)

Vizualizare

Íslenska (IS) (65.52 KB - PDF)

Vizualizare

norsk (NO) (65.84 KB - PDF)

Vizualizare

Product details

Name of medicine
Suboxone
Active substance
  • buprenorphine
  • naloxone
International non-proprietary name (INN) or common name
  • buprenorphine
  • naloxone
Therapeutic area (MeSH)
Opioid-Related Disorders
Anatomical therapeutic chemical (ATC) code
N07BC51

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Authorisation details

EMA product number
EMEA/H/C/000697
Marketing authorisation holder
Indivior Europe Limited

27 Windsor Place
Dublin 2
Ireland

Opinion adopted
27/07/2006
Marketing authorisation issued
26/09/2006
Withdrawal of marketing authorisation
11/09/2026
Revision
24

Assessment history

This page was last updated on

Share this page